AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2365538 — intervention group
Group type: COMPARATOR
Intervention: Chlorthalidone (25 mg once a day)
Number of subjects: 36
Study 227072 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiapride (300 mg/day, IM route)
Number of subjects: 30
Study 227072 — intervention group
Group type: COMPARATOR
Intervention: Reference drug
Number of subjects: 30
Study 31973115 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-SSE
Number of subjects: 118
Study 31973115 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 118
Study 31742587 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity endurance training program (3 sessions of 40 minutes per week for 8 weeks)
Number of subjects: 32
Study 31742587 — intervention group
Group type: COMPARATOR
Intervention: Nontraining group (maintained normal lifestyle)
Number of subjects: 32
Study 28577685 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (ACE inhibitor)
Number of subjects: 468
Study 28577685 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (BB)
Number of subjects: 468
Study 28577685 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 468
Study 25759969 — intervention group
Group type: EXPERIMENTAL
Intervention: TIPS
Number of subjects: 73
Study 25759969 — intervention group
Group type: COMPARATOR
Intervention: EBL plus propranolol
Number of subjects: 73
Study 26253735 — intervention group
Group type: EXPERIMENTAL
Intervention: OCT-guided Nobori biolimus-eluting stent implantation
Number of subjects: 100
Study 26253735 — intervention group
Group type: COMPARATOR
Intervention: Angiographic guidance only
Number of subjects: 100
Study 26253735 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 23979365 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ART-123 (0.06 mg/kg/d) for 6 days
Number of subjects: 750
Study 23979365 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 750
Study 21048093 — intervention group
Group type: EXPERIMENTAL
Intervention: Airtraq laryngoscope
Number of subjects: 108
Study 21048093 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 108
Study 18339140 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymoglobulin (Thymo)
Number of subjects: 90
Study 18339140 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Number of subjects: 90
Study 18339140 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab (Dac)
Number of subjects: 90
Study 17154778 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit change detection task with corrected methodological biases
Number of subjects: 0
Study 17154778 — intervention group
Group type: COMPARATOR
Intervention: Implicit change detection task
Number of subjects: 0
Study 14584548 — intervention group
Group type: EXPERIMENTAL
Intervention: Directed forgetting (DF) by items in frontal patients with right side lesions
Number of subjects: 3
Study 14584548 — intervention group
Group type: EXPERIMENTAL
Intervention: Directed forgetting (DF) by lists in temporal patients with left side lesions
Number of subjects: 3
Study 14584548 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrieval induced forgetting (RIF) in frontal patients
Number of subjects: 3
Study 14584548 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrieval induced forgetting (RIF) in temporal patients
Number of subjects: 3
Study 14584548 — intervention group
Group type: COMPARATOR
Intervention: Non-brain damaged controls
Number of subjects: 3
Study 10948466 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia for labor pain relief
Number of subjects: 3142
Study 9635652 — intervention group
Group type: EXPERIMENTAL
Intervention: Air insufflation technique (500 mL of air instilled into the stomach)
Number of subjects: 64
Study 9635652 — intervention group
Group type: COMPARATOR
Intervention: Control technique (no air insufflation)
Number of subjects: 64
Study 9635652 — intervention group
Group type: EXPERIMENTAL
Intervention: Air insufflation technique
Number of subjects: 64
Study 9635652 — intervention group
Group type: COMPARATOR
Intervention: Control technique
Number of subjects: 64
Study 8171951 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (0.1 mg prior to surgery, 0.05 mg every 30 min during surgery)
Number of subjects: 40
Study 8171951 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil (0.5 mg prior to surgery, 0.25 mg every 15 min during surgery)
Number of subjects: 40
Study 8171951 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 40
Study 8171951 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 40
Study 8171951 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl and Alfentanil
Number of subjects: 40
Study 3335192 — intervention group
Group type: EXPERIMENTAL
Intervention: Kreon, three times six capsules daily
Number of subjects: 9
Study 3335192 — intervention group
Group type: EXPERIMENTAL
Intervention: Panzytrat 20.000, three times three capsules daily
Number of subjects: 9
Study 31903807 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI + cetuximab
Number of subjects: 0
Study 31903807 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI + bevacizumab
Number of subjects: 0
Study 29789878 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-dose nut diet (75 g/day mixed nuts)
Number of subjects: 117
Study 29789878 — intervention group
Group type: COMPARATOR
Intervention: Full-dose muffin diet (three whole-wheat muffins, 188 g/day)
Number of subjects: 117
Study 29789878 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose nut diet (half portions of both nuts and muffins)
Number of subjects: 117
Study 29789878 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-dose nut diet
Number of subjects: 117
Study 27389118 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided genicular nerve pulsed RF treatment
Number of subjects: 9
Study 26023223 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking at 1.25 m/s
Number of subjects: 17
Study 23989798 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of pancreatic acinar cells
Number of subjects: 1071
Study 23989798 — intervention group
Group type: COMPARATOR
Intervention: Absence of pancreatic acinar cells
Number of subjects: 1071
Study 21417811 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone therapy (major autohemotherapy, minor autohemotherapy, and rectal ozone insufflation)
Number of subjects: 52
Study 21417811 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone therapy
Number of subjects: 52
Study 21417811 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (silymarin and/or multivitamins)
Number of subjects: 52
Study 21417811 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 52
Study 18310363 — intervention group
Group type: EXPERIMENTAL
Intervention: Transobturator tape
Number of subjects: 170
Study 18310363 — intervention group
Group type: COMPARATOR
Intervention: Tension-free vaginal tape (TVT)
Number of subjects: 170
Study 16988569 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroticism (N)
Number of subjects: 75
Study 16988569 — intervention group
Group type: EXPERIMENTAL
Intervention: N-anx (anxiety subfacet)
Number of subjects: 75
Study 16988569 — intervention group
Group type: EXPERIMENTAL
Intervention: N-dep (depression subfacet)
Number of subjects: 75
Study 14599834 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous release with steroid injection
Number of subjects: 115
Study 14599834 — intervention group
Group type: COMPARATOR
Intervention: Steroid injection alone
Number of subjects: 115
Study 11034244 — intervention group
Group type: EXPERIMENTAL
Intervention: Total gastrectomy with pancreas tail resection (Group A)
Number of subjects: 110
Study 11034244 — intervention group
Group type: COMPARATOR
Intervention: Total gastrectomy without pancreas tail resection (Group B)
Number of subjects: 110
Study 8826725 — intervention group
Group type: EXPERIMENTAL
Intervention: Picolax
Number of subjects: 150
Study 8826725 — intervention group
Group type: EXPERIMENTAL
Intervention: Picolax following a 3 day low‐residue diet
Number of subjects: 150
Study 8826725 — intervention group
Group type: COMPARATOR
Intervention: Kleen‐Prep
Number of subjects: 150
Study 7829015 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclical antibiotics (ampicillin, metronidazole, ciprofloxacin) and ursodeoxycholic acid
Number of subjects: 70
Study 7829015 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 70
Study 7829015 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclical antibiotics and ursodeoxycholic acid
Number of subjects: 70
Study 3220854 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous passive motion (CPM) devices
Number of subjects: 10
Study 3220854 — intervention group
Group type: COMPARATOR
Intervention: Supervised OT/PT (Control)
Number of subjects: 10
Study 29502508 — intervention group
Group type: EXPERIMENTAL
Intervention: Acquaintance rape scenario
Number of subjects: 348
Study 29502508 — intervention group
Group type: COMPARATOR
Intervention: Stranger rape scenario
Number of subjects: 348
Study 29502508 — intervention group
Group type: EXPERIMENTAL
Intervention: Victim race (Black)
Number of subjects: 348
Study 29502508 — intervention group
Group type: COMPARATOR
Intervention: Victim race (White)
Number of subjects: 348
Study 29904968 — intervention group
Group type: EXPERIMENTAL
Intervention: Cantharidin only
Number of subjects: 94
Study 29904968 — intervention group
Group type: EXPERIMENTAL
Intervention: Cantharidin with occlusion
Number of subjects: 94
Study 29904968 — intervention group
Group type: COMPARATOR
Intervention: Placebo with occlusion
Number of subjects: 94
Study 29904968 — intervention group
Group type: COMPARATOR
Intervention: Placebo only
Number of subjects: 94
Study 29904968 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined cantharidin arms
Number of subjects: 94
Study 29141460 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin up-titration (1,500-2,250 mg/day)
Number of subjects: 50
Study 29141460 — intervention group
Group type: COMPARATOR
Intervention: Control (maintaining low-dose metformin)
Number of subjects: 50
Study 29141460 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin up-titration
Number of subjects: 50
Study 29141460 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 50
Study 26515419 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release niacin (ERN; 1-2 g/d)
Number of subjects: 11
Study 23207512 — intervention group
Group type: EXPERIMENTAL
Intervention: Infiltrant applied for 1 min
Number of subjects: 34
Study 23207512 — intervention group
Group type: EXPERIMENTAL
Intervention: Infiltrant applied for 3 min
Number of subjects: 34
Study 23207512 — intervention group
Group type: EXPERIMENTAL
Intervention: Infiltrant applied for 5 min
Number of subjects: 34
Study 20184222 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (reference formulation)
Number of subjects: 144
Study 18383987 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (diet with > 30 g of fiber and < 16 g of saturated fat, exercise 5-6 days/week, strength training 3 days/week, stress management 10-20 minutes daily)
Number of subjects: 56
Study 18383987 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 56
Study 18383987 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 56
Study 16723101 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate (IMN) 40 mg with dinoprostone 3 mg
Number of subjects: 120
Study 16723101 — intervention group
Group type: COMPARATOR
Intervention: Placebo with dinoprostone 3 mg
Number of subjects: 120
Study 12590007 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (50 microg/day)
Number of subjects: 20
Study 12590007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10921762 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol via Diskus (cumulative doses of 200, 400, 800, 1600, and 3200 microg)
Number of subjects: 25
Study 10921762 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol via Turbuhaler (cumulative doses of 200, 400, 800, 1600, and 3200 microg)
Number of subjects: 25
Study 10921762 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 8833682 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant-treated group
Number of subjects: 0
Study 8833682 — intervention group
Group type: COMPARATOR
Intervention: Referent group without antidepressant treatment
Number of subjects: 0
Study 1452374 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem (30 mg three times a day)
Number of subjects: 15
Study 6483162 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxefazepam 10 mg
Number of subjects: 7
Study 6483162 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxefazepam 20 mg
Number of subjects: 7
Study 6483162 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxefazepam 40 mg
Number of subjects: 7
Study 6483162 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxefazepam 10 mg (2-week administration)
Number of subjects: 7
Study 6483162 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxefazepam 10 mg (self-administered at home)
Number of subjects: 7
Study 6483162 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 30496845 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP, calcium sulfate, and autologous bone graft
Number of subjects: 20
Study 30496845 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PRP, calcium sulfate, or autologous bone graft)
Number of subjects: 20
Study 30336856 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 82
Study 30336856 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 82
Study 27281305 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin 100-kcal shake
Number of subjects: 15
Study 27281305 — intervention group
Group type: EXPERIMENTAL
Intervention: Thick 100-kcal shake
Number of subjects: 15
Study 27281305 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin 500-kcal shake
Number of subjects: 15
Study 27281305 — intervention group
Group type: EXPERIMENTAL
Intervention: Thick 500-kcal shake
Number of subjects: 15
Study 25213640 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain induced by injection of hypertonic saline into vastus medialis (VM)
Number of subjects: 33
Study 25213640 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain induced by injection of hypertonic saline into rectus femoris (RF)
Number of subjects: 33
Study 25213640 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary reduction of EMG amplitude of RF
Number of subjects: 33
Study 25213640 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary reduction of EMG amplitude of VM
Number of subjects: 33
Study 21874370 — intervention group
Group type: COMPARATOR
Intervention: CPAP
Number of subjects: 35
Study 21874370 — intervention group
Group type: COMPARATOR
Intervention: ABPR-PAP
Number of subjects: 35
Study 19536166 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment
Number of subjects: 0
Study 19536166 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17364675 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical therapy
Number of subjects: 610
Study 17364675 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-point decrement in percent predicted FEV1
Number of subjects: 610
Study 17364675 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-point worsening in SOBQ
Number of subjects: 610
Study 17364675 — intervention group
Group type: EXPERIMENTAL
Intervention: Full model incorporating spirometry, PaO2, dyspnea, prior exacerbations and co-morbidity
Number of subjects: 610
Study 15734870 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12169127 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoglycoside and steroid preparation
Number of subjects: 39
Study 12169127 — intervention group
Group type: COMPARATOR
Intervention: Steroid preparation without aminoglycoside
Number of subjects: 39
Study 10451909 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal GHRH (300 micrograms)
Number of subjects: 23
Study 10451909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 8963361 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat/high fiber diet (25.5 energy‐% fat, 58.5 energy‐% carbohydrate, 3.9 g dietary fiber/MJ)
Number of subjects: 48
Study 8963361 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 48
Study 1978471 — intervention group
Group type: EXPERIMENTAL
Intervention: Remoxipride twice daily
Number of subjects: 160
Study 1978471 — intervention group
Group type: EXPERIMENTAL
Intervention: Remoxipride three times daily
Number of subjects: 160
Study 1978471 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol three times daily
Number of subjects: 160
Study 111119 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin, 2 g, intramuscularly
Number of subjects: 107
Study 111119 — intervention group
Group type: COMPARATOR
Intervention: Procaine penicillin G, 4.8 million U, intramuscularly
Number of subjects: 107
Study 31338640 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical lotion CG428, applied twice per day for 6 months
Number of subjects: 35
Study 31338640 — intervention group
Group type: COMPARATOR
Intervention: Placebo, applied twice per day for 6 months
Number of subjects: 35
Study 30641749 — intervention group
Group type: EXPERIMENTAL
Intervention: Males
Number of subjects: 500
Study 30641749 — intervention group
Group type: COMPARATOR
Intervention: Females
Number of subjects: 500
Study 27362697 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week high intensity interval plus resistance training (HITR, n = 12)
Number of subjects: 34
Study 27362697 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week high intensity continuous aerobic training plus resistance training (HCTR, n = 11)
Number of subjects: 34
Study 27362697 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control group (SED, n = 11)
Number of subjects: 34
Study 25887506 — intervention group
Group type: EXPERIMENTAL
Intervention: Linguistically adapted, evidence-based, health-promoting intervention with a person-centred approach, comprising four group meetings and one follow-up home visit by a multi-professional team.
Number of subjects: 130
Study 25887506 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified in the abstract.
Number of subjects: 130
Study 23690352 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer Assisted Relaxation Learning (CARL)
Number of subjects: 0
Study 23690352 — intervention group
Group type: COMPARATOR
Intervention: Informational pamphlet (Control)
Number of subjects: 0
Study 22080310 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback condition
Number of subjects: 20
Study 22080310 — intervention group
Group type: COMPARATOR
Intervention: Nonfeedback condition
Number of subjects: 20
Study 19566401 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring
Number of subjects: 101
Study 19566401 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 101
Study 16686574 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance training using a commercially available balance training device (BOSU)
Number of subjects: 36
Study 16686574 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 36
Study 16686574 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance training
Number of subjects: 36
Study 15232329 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 to 40 mg/d)
Number of subjects: 60
Study 15232329 — intervention group
Group type: COMPARATOR
Intervention: Imipramine (75 to 200 mg/d)
Number of subjects: 60
Study 11762737 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive counseling group (CCG)
Number of subjects: 38
Study 11762737 — intervention group
Group type: COMPARATOR
Intervention: Brief counseling group (BCG)
Number of subjects: 38
Study 9241284 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g of elemental calcium for 6 weeks
Number of subjects: 23
Study 9241284 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 23
Study 8231904 — intervention group
Group type: EXPERIMENTAL
Intervention: 17 beta‐oestradiol-releasing vaginal ring (53 mg)
Number of subjects: 26
Study 8231904 — intervention group
Group type: COMPARATOR
Intervention: Placebo ring
Number of subjects: 26
Study 3619421 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg/kg mezlocillin
Number of subjects: 8
Study 3619421 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg/kg mezlocillin
Number of subjects: 8
Study 29730331 — intervention group
Group type: EXPERIMENTAL
Intervention: One-set training
Number of subjects: 26
Study 29730331 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-sets training
Number of subjects: 26
Study 27392513 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral pedunculopontine area stimulation
Number of subjects: 6
Study 25078584 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin and Caltrate D
Number of subjects: 91
Study 25078584 — intervention group
Group type: COMPARATOR
Intervention: Caltrate D (Control)
Number of subjects: 91
Study 22095545 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosfomycin/tobramycin for inhalation (FTI) 160/40 mg
Number of subjects: 119
Study 22095545 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosfomycin/tobramycin for inhalation (FTI) 80/20 mg
Number of subjects: 119
Study 22095545 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study 20516220 — intervention group
Group type: EXPERIMENTAL
Intervention: Corrective feedback during recognition memory tasks
Number of subjects: 0
Study 20516220 — intervention group
Group type: EXPERIMENTAL
Intervention: Corrective feedback in a false-memory procedure
Number of subjects: 0
Study 20516220 — intervention group
Group type: EXPERIMENTAL
Intervention: Corrective feedback in a categorization task
Number of subjects: 0
Study 20516220 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep and shallow encoding of categorized study lists
Number of subjects: 0
Study 18482967 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led HIV/AIDS prevention intervention
Number of subjects: 3068
Study 18482967 — intervention group
Group type: COMPARATOR
Intervention: Usual teacher-led health education curriculum
Number of subjects: 3068
Study 17009499 — intervention group
Group type: EXPERIMENTAL
Intervention: Vision-haptics group
Number of subjects: 20